NCT06596135 - Open-Label Extension Study of Setmelanotide | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions

Obesity Associated With Defects in Leptin-melanocortin Pathway

Interventions

DRUG

Setmelanotide

Open-label daily injections of setmelanotide

Trial Locations (13)

University of Buffalo, Getzville

Geisinger Health System, Danville

M3 Wake Research, Inc, Raleigh

University of Florida at Gainesville, Gainesville

Vanderbilt University School of Medicine, Nashville

WR-ClinSearch, Chattanooga

University of Michigan, Ann Arbor

Marshfield Clinical Research Institute, Marshfield

Children's Minnesota, Saint Paul

Mayo Clinic - Rochester, Rochester

HonorHealth Research Institute, Scottsdale

UC San Diego- Rady Children's Hospital, San Diego

Seattle Children's Research Institute, Seattle

All Listed Sponsors

lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY